Biotech company Medlab Clinical signed a laboratory collaboration space lease agreement today with the University of New South Wales (UNSW) Sydney to establish a laboratory in the UNSW School of Biotechnology and Biomolecular Sciences, one of Australia’s most prestigious schools of scientific research and teaching.
The latest transaction builds on current collaborations the two organisations are working on, such as the NanoCelle RNA nasal delivery research program.
In a press release issued Monday, Medlab applauded the progress of the current collaboration with UNSW’s RNA Institute and the Woolcock Institute to develop spray-delivered RNA vaccines and antiviral treatments, as well as advance nasal spray-delivered insulin.
All of these projects are using Medlab’s proprietary NanoCelle delivery technology.
In early 2022, Medlab received a government grant to apply NanoCelle to an RNA nasal vaccine in collaboration with UNSW and Macquarie University to fight COVID-19 future potential epidemics.
The non-invasive vaccine is considered a first-in-class medicine delivery system.
The laboratory lease with NSW, as well as the closure of the company’s Alexandria facility and the opening of pharmaceutical facilities in botany are expected to result significant operational savings and new research development capabilities and opportunities for Medlab.
The patented delivery platform NanoCelle is wholly owned by Medlab and developed in the company’s OGTR Registered Laboratory.
